Bioquell (BQE)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 15.7 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.91 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Last ex-div: 5th Jun, paid: 1st Jul more... Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +13.5% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Bioquell plc revenues decreased 1% to L41M. Net income increased 3% to L4M. Revenues reflect Bio-decontamination segment decrease of 6% to L25.9M, Rest of World segment decrease of 10% to L13.9M. Net income reflects Testing segment income increase of 25% to L3M. Dividend per share remained flat at L0.03. Basic Earnings per Share excluding Extraordinary Items increased from L0.09 to L0.10. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 1 | 0 | 0 |
Bioquell PLC is a holding company. The Company is engaged in the principal activities of designing, manufacturing and supplying of bio-decontamination and containment equipment, related products and services to the healthcare, life sciences and defense industries, and testing, regulatory and compliance services to a range of companies, including the aerospace, telecoms and defense industries. It has two divisions: bio-decontamination (BIO) division is engaged in providing solutions based on hydrogen peroxide vapor technology to eradicate bacteria, viruses and fungi, throughout a range of applications. It also provides chemical, biological, radiological and nuclear defense filtration technology and specialist laboratory filtration equipment, and the TRaC (Testing, Regulatory and Compliance) division provides a range of services that include environmental testing, telecoms testing, radio testing, electromagnetic compatibility testing, safety testing, CE Mark testing and stress analysis.
Directors: Nicholas Adams (CEO) , Mark Bodeker (CFO) , Georgina Pope (Secy.) ,
No. of Employees: 431 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 41,793,949 |
| Free Float | 22.6m (54.0%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Fledgling , FTSE Fledgling XIT, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | 52 Royce Close West Portway, ANDOVER, SP10 3TS, United Kingdom |
| Web | http://www.bioquellplc.com/ |
| Phone | +44 1264 835835 |
| Contact | Georgina Pope (Secy.) |
| Registrar | Capita Registrars (Kent) |
| Auditors | Deloitte LLP |
| 13th May | Result of AGM |
| 13th May | Interim Management Statement |
| 8th May | Blocklisting Interim Review |
| 25th Apr | Director/PDMR Shareholding |
| 11th Apr | Annual Financial Report |
| 19th Mar | Annual Financial Report |
Recent ↓
